TGTX Stock Price History and Quote Analysis Insights for Investors
TG Therapeutics, Inc.
Stock Price Today
TG Therapeutics, Inc. (TGTX) stock surged +0.89%, trading at $33.13 on NASDAQ, up from the previous close of $32.84. The stock opened at $32.94, fluctuating between $32.92 and $33.29 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Company Information
| Employees | 319 |
| Beta | 2.19 |
| Sales or Revenue | $233.66M |
| 5Y Sales Change% | 816.24% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
TG Therapeutics, Inc. (NASDAQ: TGTX) stock price is $33.13 in the last trading session. During the trading session, TGTX stock reached the peak price of $33.29 while $32.92 was the lowest point it dropped to. The percentage change in TGTX stock occurred in the recent session was 0.89% while the dollar amount for the price change in TGTX stock was $0.29.
The NASDAQ listed TGTX is part of Biotechnology industry that operates in the broader Healthcare sector. TG Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Jenna Bosco
Senior Vice President of Corporation Communications
Mr. Adam Waldman
Chief Commercialization Officer
Mr. Sean A. Power CPA, CPA
Chief Financial Officer, Corporation Sec. & Treasurer
TGTX's closing price is 155.76% higher than its 52-week low of $12.84 where as its distance from 52-week high of $36.84 is -10.86%.
Number of TGTX employees currently stands at 319.
Official Website of TGTX is: https://www.tgtherapeutics.com
TGTX could be contacted at phone 212 554 4484 and can also be accessed through its website. TGTX operates from 2 Gansevoort Street, New York, NY 10014, United States.
TGTX stock volume for the day was 46.88K shares. The average number of TGTX shares traded daily for last 3 months was 3.61M.
The market value of TGTX currently stands at $5.16B with its latest stock price at $33.13 and 155.67M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com